Cancer research has always been a high-stakes game of precision, persistence, and possibility. In today’s world of cutting-edge biologics and targeted therapies, the spotlight is increasingly shifting toward one key delivery method: injectables. Whether it’s monoclonal antibodies, antibody-drug conjugates, cytokines, or next-generation immunotherapies, these life-saving innovations often hinge on the complexity and quality, of their injectable formulation. Behind every oncology breakthrough is a carefully tuned strategy of science, scale, and sterility.
As the global oncology pipeline surges past 2,000 active assets, drug developers face mounting pressure to formulate, fill, and launch therapies faster, smarter, and with fewer missteps. Yet for early-phase developers and smaller biotechs, this landscape can be overwhelming. Navigating the nuances of injectable formulation (excipient compatibility, reconstitution profiles, API stability, and more) requires a level of precision that leaves no room for error. When the stakes are measured in patient outcomes, every detail matters.
That’s why this article takes a moment to pause and explore where injectable drug development intersects with the frontlines of cancer innovation. It’s not just about the science of what’s possible, but also about the infrastructure, partnerships, and processes required to get there. And with the upcoming 2025 European Association for Cancer Research (EACR) Congress in Lisbon, Portugal on the horizon, there’s no better time to examine the current trajectory of injectable oncology products.
For woman-owned CDMO Singota Solutions, the mission is clear: help clients progress their oncology molecules from bench to clinicals with unmatched attention to detail and quality. With deep roots in Bloomington, Indiana and 3 strategic operations outside of the U.S. (including Basel and Balerna, Switzerland and Rovello Porro, Italy), Singota is uniquely positioned to support global efforts in oncology development.
But before we dive into what makes Singota stand out, let’s first unpack the state of cancer injectables today, the formulation factors at play, and the shifting demands shaping this vital corner of the drug development world.